- Stocks
- Healthcare
- NYSE: BSX

Price (delayed)

$46.6

Market cap

$66.75B

P/E Ratio

113.66

Dividend/share

N/A

EPS

$0.41

Enterprise value

$74.99B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology,

Boston Scientific's gross profit has increased by 12% YoY

The revenue has increased by 10% YoY

BSX's quick ratio is down by 31% year-on-year but it is up by 11% since the previous quarter

The P/E is 48% above the last 4 quarters average of 76.6 and 24% above the 5-year quarterly average of 91.5

The EPS has decreased by 47% YoY and by 28% from the previous quarter

What are the main financial stats of BSX

Market
Valuations
Earnings

Shares outstanding

1.43B

Market cap

$66.75B

Enterprise value

$74.99B

Price to earnings (P/E)

113.66

Price to book (P/B)

3.78

Price to sales (P/S)

5.31

EV/EBIT

55.22

EV/EBITDA

30.12

EV/Sales

5.97

Revenue

$12.57B

EBIT

$1.36B

EBITDA

$2.49B

Free cash flow

$643M

Per share
Balance sheet
Liquidity

EPS

$0.41

Free cash flow per share

$0.45

Book value per share

$12.32

Revenue per share

$8.78

TBVPS

$9.11

Total assets

$31.95B

Total liabilities

$14.31B

Debt

$8.58B

Equity

$17.64B

Working capital

$1.6B

Debt to equity

0.49

Current ratio

1.45

Quick ratio

0.62

Net debt/EBITDA

3.31

Margins
Efficiency
Dividend

EBITDA margin

19.8%

Gross margin

68.8%

Net margin

5.2%

Operating margin

11.7%

Return on assets

1.9%

Return on equity

3.5%

Return on invested capital

7.8%

Return on capital employed

4.8%

Return on sales

10.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Boston Scientific stock price performed over time

Intraday

1.04%

1 week

5.55%

1 month

11.14%

1 year

17.68%

YTD

9.7%

QTD

20.32%

How have Boston Scientific's revenue and profit performed over time

Revenue

$12.57B

Gross profit

$8.65B

Operating income

$1.48B

Net income

$652M

Gross margin

68.8%

Net margin

5.2%

Boston Scientific's net margin has decreased by 49% YoY and by 28% QoQ

Boston Scientific's net income has decreased by 44% YoY and by 26% QoQ

Boston Scientific's operating income has increased by 44% YoY

BSX's operating margin is up by 31% year-on-year

What is Boston Scientific's growth rate over time

What is Boston Scientific stock price valuation

P/E

113.66

P/B

3.78

P/S

5.31

EV/EBIT

55.22

EV/EBITDA

30.12

EV/Sales

5.97

The P/E is 48% above the last 4 quarters average of 76.6 and 24% above the 5-year quarterly average of 91.5

The EPS has decreased by 47% YoY and by 28% from the previous quarter

The stock's price to book (P/B) is 14% less than its 5-year quarterly average of 4.4 but 11% more than its last 4 quarters average of 3.4

The equity has grown by 7% YoY and by 2.3% from the previous quarter

BSX's P/S is 11% above its last 4 quarters average of 4.8 and 6% above its 5-year quarterly average of 5.0

The revenue has increased by 10% YoY

How efficient is Boston Scientific business performance

The return on equity has declined by 49% year-on-year and by 29% since the previous quarter

The return on assets has declined by 46% year-on-year and by 27% since the previous quarter

The ROS has decreased by 23% YoY and by 18% from the previous quarter

BSX's ROIC is down by 17% from the previous quarter and by 15% YoY

What is BSX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BSX.

How did Boston Scientific financials performed over time

Boston Scientific's total assets is 123% more than its total liabilities

BSX's quick ratio is down by 31% year-on-year but it is up by 11% since the previous quarter

BSX's current ratio is up by 11% since the previous quarter but it is down by 6% year-on-year

Boston Scientific's debt is 51% lower than its equity

Boston Scientific's debt to equity has decreased by 11% YoY and by 6% from the previous quarter

The equity has grown by 7% YoY and by 2.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.